Shionogi Shifts Sales Focus To Crestor
This article was originally published in PharmAsia News
Japan's Shionogi plans to step up its promotions in hospitals to create an 83 percent increase in domestic sales of its Crestor (rosuvastatin) cholesterol drug by next March. The company said it would train some of its 1,450 medical representatives to promote use of the drug in hospitals instead of only to clinics, and to track the frequency with which it is prescribed. The focus on the statin marks a shift by Shionogi away from anti-microbial agents and their declining sales to metabolic syndrome medicines. (Click here for more - a subscription may be required
You may also be interested in...
TOKYO - Shionogi & Co. of Osaka is projecting domestic sales of its cholesterol treatment Crestor (rosuvastatin) to grow 82 percent in fiscal 2008 to ¥19 billion ($180 million), thanks to its lower price and additional efficacy compared to competitor Pfizer's Lipitor (atorvastatin), a company official said July 2
Lawyer asks US FDA to require another trial before licensing Mesoblast’s stem cell therapy for children with SR-aGVHD; Incyte’s Jakafi is only product approved for the indication.
Hanmi licenses out GLP-1/glucagon receptor dual agonist for NASH to Merck, in a deal worth up to $870m, marking a positive turn for the Korean firm's pipeline after Janssen returned rights last year.